Despite the challenging market conditions, Biodesix Inc. (BDSX) has shown remarkable resilience, steadily climbing in value. From a valuation perspective, the company's current valuation stands at
148.28M, which, when compared to its market capitalization of
120.7M, indicates a potential undervaluation. This discrepancy may present an attractive entry point for investors. However, it's worth noting that the company's Z score of
-4.25 suggests a potential risk of bankruptcy in the near future. Additionally, Biodesix reported a loss of
0.67 per share for the current year, which could be a concern for potential investors. Despite these challenges, the company's resilience amidst a market downturn could make it a worthwhile consideration for risk-tolerant investors.
Rigorous look on BiodesixInc
The company, Biodesix Inc, currently has $31.85 million in liabilities, with a Debt to Equity (D/E) ratio of 3.2. This indicates that Biodesix Inc significantly relies on borrowed funds to finance its operations. We offer trading advice that aligns with the prevailing expert consensus on Biodesix Inc. Our advanced recommendation engine utilizes a multidimensional algorithm to analyze the company's growth potential. This analysis is based on all available technical and fundamental data at the time.
We determine the current worth of Biodesix using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Biodesix based exclusively on its
fundamental and basic
technical indicators. By analyzing Biodesix's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of
Biodesix's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Biodesix. We calculate exposure to Biodesix's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Biodesix's related companies.
Watch out for price decline
Please consider monitoring Biodesix on a daily basis if you are holding a position in it. Biodesix is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Biodesix stock to be traded above the $1 level to remain listed. If Biodesix stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Biodesix Investment Alerts
Biodesix investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Biodesix performance across your portfolios.Please check all
investment alerts for Biodesix
Biodesix Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Biodesix value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biodesix competition to find
correlations between indicators driving the intrinsic value of Biodesix.
Biodesix Gross Profit
Biodesix Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Biodesix previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Biodesix Gross Profit growth over the last 10 years. Please check Biodesix's
gross profit and other
fundamental indicators for more details.
Another Deeper Perspective
The company reported the previous year's revenue of 38.21
M. Net Loss for the year was (65.45
M) with profit before overhead, payroll, taxes, and interest of 24.06
M.
| 2020 | 2021 | 2022 | 2023 (projected) |
Interest Expense | 7.6 M | 4.51 M | 8.07 M | 7.27 M | Gross Profit | 23.56 M | 23.99 M | 24.06 M | 24.95 M |
Margins Breakdown
BiodesixInc profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or BiodesixInc itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of BiodesixInc profit margins.
| EBITDA Margin | (1.46) |
| Gross Margin | 0.59 |
| Profit Margin | (1.85) |
BiodesixInc Average Assets is fairly stable at the moment. Also, BiodesixInc Average Equity is increasing over the last 5 years. The previous year's value of BiodesixInc Average Equity was 8,943,125. Despite the general market downturn, Biodesix Inc. (BDSX) has demonstrated a remarkable resilience, with its stock steadily climbing. The company, which trades on the NASDAQ, has a current valuation of
$148.28M, with a total of 4.5M shares floating in the market.
Interestingly, the number of shares shorted has decreased from 229.5K in the previous month to 143.9K, indicating a growing confidence among investors. However, Biodesix's financials reveal a challenging picture. The company reported a net income loss of $65.4M and an operating income loss of $50.5M, largely due to total operating expenses of $74.6M. The cost of revenue stood at $14.2M, contributing to a negative operating margin of -1.24. Despite this, Biodesix managed to maintain an end period cash flow of $43.2M and net assets of $92.91M. The company's current ratio stands at 0.64X, indicating a potential liquidity risk. However, Biodesix seems to be managing its debts well with short and long-term debt totaling $31.9M, significantly lower than its total assets of
$92.9M. Despite the challenges, Wall Street has set a target price of $4.25 for the stock, hinting at its potential upside. With a downside deviation of 6.19, investors need to carefully consider the risks associated with this stock. .
Will BiodesixInc pull back in November 2023?
The potential upside for Biodesix Inc. has recently been revised to 10.2, indicating a possible decrease in volatility. This suggests that the stock may face a pullback in November 2023. Investors are advised to closely monitor this situation, as a decrease in volatility often signals an impending price correction. Despite the potential for short-term turbulence, the company's long-term prospects remain solid. As always, investors should conduct comprehensive research before making any investment decisions. As of October 22, Biodesix Inc. displays a Risk Adjusted Performance of 0.0808, a downside deviation of 6.19, and a Mean Deviation of 4.72. Biodesix Inc.'s
technical analysis provides a methodology to utilize historical prices and volume patterns to predict the direction of the company's future prices. In other words, this information can be used to determine if the company will mirror its model of historical prices and volume momentum, or if the prices will eventually revert.
We have been able to interpolate and collect nineteen technical drivers for Biodesix Inc., which can be compared to its
competitors. Please verify Biodesix Inc.'s coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to determine if Biodesix Inc. is priced correctly, assuming the market reflects its regular price of 1.71 per share. Also, please recheck Biodesix Inc.'s total risk alpha, which currently stands at 1.89, to confirm the company's sustainability in the future. Despite the modest market slide, BiodesixInc (BDSX) continues to exhibit a slow but steady rise. The company's real value is currently estimated at
2.45, which is significantly higher than its market value of
1.71. This discrepancy indicates a potential undervaluation, making it an attractive buy for investors. The overall
analyst consensus for BDSX is a 'Buy', with a target price estimated value of 5, further reinforcing its investment potential. However, investors should be mindful of the fact that there is only one analyst estimate available, which may limit the diversity of perspectives on the stock's
future performance. As we approach the fiscal year end in December, investors should keep a close eye on BDSX's performance and consider it as a potential addition to their portfolios. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Biodesix. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
